TABLE 3.
Anterior chamber inflammation in the control group and in eyes treated with intravitreal bevacizumab.
| Laser flare photometry (photons/ms) | p | ||||||
|---|---|---|---|---|---|---|---|
| Control group | Bevacizumab group | ||||||
| n° (eyes) | Mean | SD | n° (eyes) | Mean | SD | ||
| Before treatment | 17 | 7.32 | 3.22 | 48 | 7.51 | 3.42 | 0.840 |
| 1 day after 1st injection | 18 | 8.56 | 3.75 | 47 | 7.34 | 3.18 | 0.253 |
| 30 days after 1st injection | 18 | 7.03 | 3.39 | 46 | 7.07 | 3.26 | 0.893 |
| 1 day after 2nd injection | 19 | 7.80 | 1.98 | 47 | 8.03 | 3.07 | 0.860 |
| 30 days after 2nd injection | 19 | 6.68 | 2.47 | 41 | 7.74 | 4.24 | 0.546 |
| 1 day after 3rd injection | 17 | 6.49 | 3.24 | 38 | 7.60 | 3.86 | 0.233 |
| 30 days after 3rd injection | 18 | 7.49 | 4.76 | 48 | 6.98 | 2.62 | 0.565 |
SD, standard deviation; p, p value: p-values estimated with Mann-Whitney U test.